147 related articles for article (PubMed ID: 17888650)
1. The putative roles of the ubiquitin/proteasome pathway in resistance to anticancer therapy.
Smith L; Lind MJ; Drew PJ; Cawkwell L
Eur J Cancer; 2007 Nov; 43(16):2330-8. PubMed ID: 17888650
[TBL] [Abstract][Full Text] [Related]
2. The proteasome: a worthwhile target for the treatment of solid tumours?
Milano A; Iaffaioli RV; Caponigro F
Eur J Cancer; 2007 May; 43(7):1125-33. PubMed ID: 17379504
[TBL] [Abstract][Full Text] [Related]
3. The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases.
Wang J; Maldonado MA
Cell Mol Immunol; 2006 Aug; 3(4):255-61. PubMed ID: 16978533
[TBL] [Abstract][Full Text] [Related]
4. Proteasome inhibitors in cancer therapy: a novel approach to a ubiquitous problem.
Landis-Piwowar KR
Clin Lab Sci; 2012; 25(1):38-44. PubMed ID: 22458048
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibitors in cancer therapy: lessons from the first decade.
Orlowski RZ; Kuhn DJ
Clin Cancer Res; 2008 Mar; 14(6):1649-57. PubMed ID: 18347166
[TBL] [Abstract][Full Text] [Related]
6. Ubiquitin-proteasome-mediated local protein degradation and synaptic plasticity.
Hegde AN
Prog Neurobiol; 2004 Aug; 73(5):311-57. PubMed ID: 15312912
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of proteasome inhibitor action and resistance in cancer.
McConkey DJ; Zhu K
Drug Resist Updat; 2008; 11(4-5):164-79. PubMed ID: 18818117
[TBL] [Abstract][Full Text] [Related]
8. The vital link between the ubiquitin-proteasome pathway and DNA repair: impact on cancer therapy.
Motegi A; Murakawa Y; Takeda S
Cancer Lett; 2009 Sep; 283(1):1-9. PubMed ID: 19201084
[TBL] [Abstract][Full Text] [Related]
9. Dysfunction of the ubiquitin-proteasome system in multiple disease conditions: therapeutic approaches.
Paul S
Bioessays; 2008 Nov; 30(11-12):1172-84. PubMed ID: 18937370
[TBL] [Abstract][Full Text] [Related]
10. The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?
Cvek B; Dvorak Z
Drug Discov Today; 2008 Aug; 13(15-16):716-22. PubMed ID: 18579431
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib in combination with other therapies for the treatment of multiple myeloma.
Orlowski RZ
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S16-20. PubMed ID: 19791424
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibition: mechanism of action.
DeMartino GN
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S5-9. PubMed ID: 19791423
[TBL] [Abstract][Full Text] [Related]
13. The roles of ubiquitin and 26S proteasome in human obesity.
Chang TL; Chang CJ; Lee WY; Lin MN; Huang YW; Fan K
Metabolism; 2009 Nov; 58(11):1643-8. PubMed ID: 19616267
[TBL] [Abstract][Full Text] [Related]
14. Highlights in experimental therapeutics.
Burger AM
Cancer Lett; 2007 Jan; 245(1-2):11-21. PubMed ID: 16647200
[TBL] [Abstract][Full Text] [Related]
15. Concise review: role and function of the ubiquitin-proteasome system in mammalian stem and progenitor cells.
Naujokat C; Sarić T
Stem Cells; 2007 Oct; 25(10):2408-18. PubMed ID: 17641241
[TBL] [Abstract][Full Text] [Related]
16. The role of proteasome in malignant diseases.
Moran E; Nencioni A
J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
Dorsey BD; Iqbal M; Chatterjee S; Menta E; Bernardini R; Bernareggi A; Cassarà PG; D'Arasmo G; Ferretti E; De Munari S; Oliva A; Pezzoni G; Allievi C; Strepponi I; Ruggeri B; Ator MA; Williams M; Mallamo JP
J Med Chem; 2008 Feb; 51(4):1068-72. PubMed ID: 18247547
[TBL] [Abstract][Full Text] [Related]
18. Emerging roles for the ubiquitin-proteasome system and autophagy in pancreatic beta-cells.
Hartley T; Brumell J; Volchuk A
Am J Physiol Endocrinol Metab; 2009 Jan; 296(1):E1-10. PubMed ID: 18812463
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibition up-regulates p53 and apoptosis-inducing factor in chondrocytes causing severe growth retardation in mice.
Zaman F; Menendez-Benito V; Eriksson E; Chagin AS; Takigawa M; Fadeel B; Dantuma NP; Chrysis D; Sävendahl L
Cancer Res; 2007 Oct; 67(20):10078-86. PubMed ID: 17942942
[TBL] [Abstract][Full Text] [Related]
20. Physalin B, a novel inhibitor of the ubiquitin-proteasome pathway, triggers NOXA-associated apoptosis.
Vandenberghe I; Créancier L; Vispé S; Annereau JP; Barret JM; Pouny I; Samson A; Aussagues Y; Massiot G; Ausseil F; Bailly C; Kruczynski A
Biochem Pharmacol; 2008 Aug; 76(4):453-62. PubMed ID: 18577376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
